Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Principal Officers;
Election of Directors; Appointment of Principal Officers.
Appointment of Director
On August 6, 2026, the board
of directors (the “Board”) of the Company appointed Elena Ridloff as a member of the Board, effective immediately. As a Class
I director, Ms. Ridloff’s term lasts until the Company’s 2027 annual meeting of stockholders, and until her successor is duly
elected and qualified, or until her earlier death, resignation or removal.
Elena Ridloff, CFA,
age 46, has served as a member of the board of directors of Kymera Therapeutics, Inc. since March 2021. Ms. Ridloff has served as the
Chief Financial Officer of Sionna Therapeutics, Inc., a publicly traded life sciences company, since September 2021. Ms. Ridloff previously
served as the Executive Vice President and Chief Financial Officer of ACADIA Pharmaceuticals Inc., or ACADIA, a publicly traded pharmaceutical
company. Ms. Ridloff joined ACADIA in April 2018 as Senior Vice President, Investor Relations, where she led investor and financial communications
activities, and served as ACADIA’s Chief Financial Officer from October 2018 to September 2021. Before ACADIA, Ms. Ridloff held
various roles at Alexion Pharmaceuticals, Inc., or Alexion, including Executive Director, Investor Relations from April 2014 to January
2016, and Vice President, Investor Relations from January 2016 to March 2018. Prior to joining Alexion, Ms. Ridloff served as the Chief
Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations
counsel to the life sciences industry, from January 2012 to April 2014. Ms. Ridloff also spent over a decade as an institutional investor
and from July 2005 to January 2012 served as Managing Director at Maverick Capital, a hedge fund, where she was responsible for investments
in the biotechnology, pharmaceutical, medical device and life science sectors. From September 2020 until its acquisition by Concentra
Biosciences, LLC in June 2025, Ms. Ridloff served on the board of directors of Kronos Bio, Inc. Ms. Ridloff earned her B.A. in history
and sociology of science from the University of Pennsylvania and is a Chartered Financial Analyst. We believe Ms. Ridloff is qualified
to serve on our board of directors due to her financial and accounting expertise and her experience in the finance and life sciences industries.
In connection with her appointment
as a director, Ms. Ridloff received an inaugural grant of options to purchase up to a total of 50,740 shares of the Company’s common
stock, effective August 6, 2026, which vest on a monthly basis over a three year period. The foregoing options have an exercise price
per share equal to the closing price of the Company’s common stock on The Nasdaq Stock Market on August 6, 2026 (the “Award”).
Ms. Ridloff will also receive cash compensation for her service on the Board in accordance with the Company’s non-employee director
compensation policy, as described in the Company’s most recent proxy statement, as may be adjusted from time to time as set forth
in the Company’s filings and reports made with the Securities and Exchange Commission.
There is no relationship or
agreement between Ms. Ridloff and any other person pursuant to which she was appointed as a director of the Company and there is no family
relationship between Ms. Ridloff and any of the Company’s directors or executive officers. The Company is not aware of any transaction
involving Ms. Ridloff which would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act, other than
as set forth in this Current Report on Form 8-K.
Ms. Ridloff and the Company
will enter into a customary indemnity agreement, substantially in the form filed as Exhibit 10.7 of the Company’s Annual Report
on Form 10-K for the year ended December 31, 2025, filed with the Commission on February 26, 2026.
Resignation of Dr. Daniel Vitt
On August 6, 2026, Daniel Vitt,
resigned as a member of the Board. The resignation of Dr. Vitt was not the result of any disagreement with the Company on any matter relating
to the Company’s operations, policies, or practices. The Board is deeply grateful for Dr. Vitt’s service, dedication, and
contributions to the Company.
As previously disclosed, on
May 22, 2026, Daniel Vitt, resigned as the Chief Executive Officer of the Company, effective June 1, 2026. Since June 1, 2026, Dr. Vitt
continued to retain responsibility for scientific strategy and portfolio advancement and there were no changes to the Company’s
compensation arrangements with Dr. Vitt.
On August 7, 2026, the Company
entered into a Separation Agreement (the “Separation Agreement”) with Dr. Vitt, pursuant to which Dr. Vitt’s employment
with the Company terminated on such date (the “Separation Date”). Pursuant to the Separation Agreement, Dr. Vitt agreed to
serve as Chair of the Company’s Scientific Advisory Board (the “SAB”).
In addition, Dr. Vitt entered
into an agreement with Immunic AG, a wholly owned subsidiary of the Company (the “Company Subsidiary”), pursuant to which
he ceased to be a member of the Executive Board of the Company Subsidiary as of the Separation Date, and his service agreement with the
Company Subsidiary, dated December 18, 2023 (the “Service Agreement”), terminated without any ongoing obligations. From the
date of the Separation Agreement through the Separation Date, (a) the Company agreed to pay Dr. Vitt all accrued salary earned through
the Separation Date, subject to standard payroll deductions and withholdings, and (b) the Company Subsidiary agreed to pay Dr. Vitt all
accrued salary earned under the Service Agreement through the Separation Date, subject to standard payroll deductions and withholdings,
and the Company and the Company Subsidiary agreed to pay Dr. Vitt for all accrued and unused vacation days on the Company’s first
regular payroll payday following the Separation Date.
Commencing on the Separation Date,
Dr. Vitt began serving as a consultant to the Company Subsidiary for an initial period of twelve
(12) months (the “Consulting
Period”), in addition to serving as Chair of the SAB, providing consulting services on an as-needed basis for up to fifteen (15)
hours per month, in exchange for a monthly retainer of €15,000. Dr. Vitt also agreed to non-competition and non- solicitation covenants
through the Consulting Period and for six (6) months following the date he ceases to be a member of the SAB. In addition, the Company
and the Company Subsidiary agreed to provide Dr. Vitt with severance benefits, subject to his timely execution and non-revocation of a
release of claims in favor of the Company, including (i) a salary payment consisting of his base salary and the monthly installment of
his fixed annual salary under the Service Agreement, in each case for a period of sixteen and one-half (16.5) months following the Separation
Date, of which the first twelve (12) installments (equal to $670,000 in the aggregate) will be paid in a lump sum on the first regular
payroll payday following the Release Effective Date (as defined in the Separation Agreement) and the remaining four and one-half (4.5)
months will be paid in five (5) monthly installments (the last at half pay) beginning on the first regular payroll payday following the
one-year anniversary of the Release Effective Date, (ii) an aggregate bonus payment of $276,375 (or the Euro equivalent), equal to seventy-five
percent (75%) of his target bonus for fiscal year 2026, payable in a lump sum on or before the Company’s first regular payroll payday
following the Release Effective Date, and (iii) reimbursement from the Company Subsidiary for the monthly cost of obtaining healthcare
in Germany, in an amount not to exceed €1,500 per month, for a period of eighteen (18) months following the Release Effective Date.
Additionally, 100% of Dr. Vitt’s outstanding equity awards vested as of the Separation Date, and Dr. Vitt will have three (3) years
following the Separation Date to exercise any vested equity awards. The Company also agreed to reimburse Dr. Vitt for legal fees incurred
in connection with the negotiation of the Separation Agreement, up to a maximum of $20,000.
The foregoing description of
the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation
Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.